← Back to Search

Chemotherapy

Amifostine + Chemotherapy for Advanced Cancer

Phase 1
Waitlist Available
Research Sponsored by The Cleveland Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Performance status: ECOG 0-2 SWOG 0-2
Hepatic: Bilirubin no greater than 1.5 mg/dL
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is studying amifostine to see how well it works in combination with chemotherapy in treating patients with advanced cancer.

Who is the study for?
This trial is for adults with advanced cancers like leukemia, lymphoma, and solid tumors that respond to cyclophosphamide/carboplatin or are refractory to standard treatments. Participants must have certain blood cell counts, not be pregnant or nursing, use contraception if fertile, have no severe heart disease or psychosis, and a life expectancy of at least 3 months.Check my eligibility
What is being tested?
The study is testing the effectiveness of amifostine combined with chemotherapy in patients with advanced cancer. Amifostine is intended to protect healthy cells from the harmful side effects of chemotherapy drugs.See study design
What are the potential side effects?
Potential side effects may include nausea, vomiting, low blood pressure (especially following injection), dizziness upon standing up due to lowered blood pressure, and allergic reactions. Chemotherapy can also cause fatigue, hair loss, mouth sores and increased risk of infections.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can take care of myself and perform daily activities.
Select...
My bilirubin level is 1.5 mg/dL or lower.
Select...
I am 18 years old or older.
Select...
I do not have severe heart disease.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

The Cleveland ClinicLead Sponsor
1,019 Previous Clinical Trials
1,365,045 Total Patients Enrolled
9 Trials studying Multiple Myeloma
175 Patients Enrolled for Multiple Myeloma
George Thomas Budd, MDStudy ChairThe Cleveland Clinic
3 Previous Clinical Trials
4,794 Total Patients Enrolled

Media Library

Combination Chemotherapy (Chemotherapy) Clinical Trial Eligibility Overview. Trial Name: NCT00004036 — Phase 1
Multiple Myeloma Research Study Groups:
Multiple Myeloma Clinical Trial 2023: Combination Chemotherapy Highlights & Side Effects. Trial Name: NCT00004036 — Phase 1
Combination Chemotherapy (Chemotherapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00004036 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there available slots for participants in this research endeavor?

"According to the clinicaltrials.gov database, this experiment is no longer accepting enrollees. It was initiated on November 1st 1997 and last updated 18th December 2013. Alternatively, there are 4,910 other trials that remain open for new participants at present."

Answered by AI

Has this remedy obtained authorization from the Food and Drug Administration?

"Based on the limited data collected, Power's assessment is that this treatment holds a low level of safety, evidenced by its Phase 1 status."

Answered by AI
~1 spots leftby Mar 2025